STEP Study

Last updated

The STEP Study was a Phase IIb clinical trial intended to study the efficacy of an experimental HIV vaccine based on a human adenovirus 5 (HAdV-5) vector. The study was conducted in North and South America, the Caribbean, and Australia. A related study (the "Phambili trial") using the same experimental vaccine was conducted simultaneously in South Africa. These trials were co-sponsored by Merck, the HIV Vaccine Trials Network (HVTN), and the National Institute of Allergy and Infectious Diseases (NIAID), and had an Oversight Committee consisting of representatives from these three organizations. In South Africa the trial was overseen by the South African AIDS Vaccine Initiative. [1]

Contents

These trials were terminated before their scheduled conclusion, when the Data Safety Monitoring Board determined that the vaccine was not preventing HIV infection, and was possibly enhancing susceptibility to HIV infection in some of the study participants. [2]

Design

The study was a multicenter, double-blinded, randomized, placebo-controlled phase II proof-of-concept trial which involved administering an experimental vaccine (the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine) to nearly 3,000 healthy HIV-negative (uninfected) volunteers. [3] Enrollment began in North and South America, the Caribbean and Australia in December 2004, and was completed in March 2007. Enrollment in the South African arm of the trial began in early 2007 and ended in September 2007. Candidates for enrollment into the study were men and women identified as high risk for acquiring HIV infection but who were currently HIV-negative. [4]

The vaccine contained three separate replication-defective vectors based on Human Adenovirus C serotype 5 (HAdV-5). Each of the three vectors expressed a single gene encoding a protein from the HIV virus: gag, pol, or nef. It was hoped that the adenovirus vectors would carry these HIV-1 genes into the cell, and that this would result in the development of a cell-mediated immune response that would confer a degree of immunity to the HIV virus. [2]

Findings

24 of the 741 men in the vaccine group and 21 men of 762 in the placebo group had tested HIV-positive. [3] [5] The protocol expected that the group which had received the vaccine would have a lower or equal infection rate as compared to the control group, but this was not seen. In fact, certain groups of the vaccine recipients were seen to have a higher risk of HIV infection as compared to the placebo group.

While almost everyone enrolled in the STEP study had received the full course of the vaccine when the vaccination cessation was announced, no one in Phambili, the African trial, had been entirely vaccinated.[ citation needed ]

Response

On September 21, 2007 sponsors of the STEP study announced that further vaccination would cease and that vaccination in the Phambili Trial would be paused pending review. [6] On October 23, 2007 the sponsors announced that the Phambili Trial would stop further immunizations. [7]

By November 2007 all participants were unblinded when researchers informed them whether they had received the vaccine or placebo. [8]

Alan Aderem of Seattle Biomed stated that "the experimental inoculation... actually increased the chances that some people would later acquire HIV." [9]

In May 2012 The New York Times reported that a study confirmed that the vaccine given to volunteers in the STEP Study made them more likely, not less, to become infected with HIV. [10]

Related Research Articles

<span class="mw-page-title-main">HIV vaccine development</span> In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals.

<i>Adenoviridae</i> Family of viruses

Adenoviruses are medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Their name derives from their initial isolation from human adenoids in 1953.

This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.

<span class="mw-page-title-main">Kennel cough</span> Upper respiratory infection affecting dogs

Kennel cough is an upper respiratory infection affecting dogs. There are multiple causative agents, the most common being the bacterium Bordetella bronchiseptica, followed by canine parainfluenza virus (CPIV), and to a lesser extent canine coronavirus. It is highly contagious; however, adult dogs may display immunity to reinfection even under constant exposure. Kennel cough is so named because the infection can spread quickly among dogs in the close quarters of a kennel or animal shelter.

Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine against smallpox and mpox, having fewer side effects than smallpox vaccines derived from other poxviruses.

A T-cell vaccine is a vaccine designed to induce protective T-cells.

<span class="mw-page-title-main">HIV Vaccine Trials Network</span>

The HIV Vaccine Trials Network (HVTN) is a non-profit organization which connects physicians and scientists with activists and community educators for the purpose of conducting clinical trials seeking a safe and effective HIV vaccine. Collaboratively, researchers and laypeople review potential vaccines for safety, immune response, and efficacy. The HVTN is a network for testing vaccines, and while its members may also work in vaccine development for other entities, the mission of the HVTN does not include vaccine design.

<span class="mw-page-title-main">Vaccine efficacy</span> Reduction of disease among the vaccinated comparing to the unvaccinated

Vaccine efficacy or vaccine effectiveness is the percentage reduction of disease cases in a vaccinated group of people compared to an unvaccinated group. For example, a vaccine efficacy or effectiveness of 80% indicates an 80% decrease in the number of disease cases among a group of vaccinated people compared to a group in which nobody was vaccinated. When a study is carried out using the most favorable, ideal or perfectly controlled conditions, such as those in a clinical trial, the term vaccine efficacy is used. On the other hand, when a study is carried out to show how well a vaccine works when they are used in a bigger, typical population under less-than-perfectly controlled conditions, the term vaccine effectiveness is used.

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax’s development platform uses Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated.

RV 144, or the Thai trial, was an HIV vaccine clinical trial that was conducted in Thailand between 2003 and 2006. It used a combination of two HIV vaccines that had each failed in earlier trials. Participants were vaccinated over the course of 24 weeks beginning in October 2003 and were then tested for HIV until July 2006. The results of the study were publicized in September 2009. The initial report showed that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. This reduction was not large enough for the Ministry of Public Health in Thailand to support approving the vaccine; it would have licensed it if the reduction had been 50% or more.

HVTN 505 is a clinical trial testing an HIV vaccine regimen on research participants. The trial is conducted by the HIV Vaccine Trials Network and sponsored by the National Institute of Allergy and Infectious Diseases. Vaccinations were stopped in April 2013 due to initial results showing that the vaccine was ineffective in preventing HIV infections and lowering viral load among those participants who had become infected with HIV. All study participants will continue to be monitored for safety and any long-term effects.

MVA-B, or Modified Vaccinia Ankara B, is an HIV vaccine created to give immune resistance to infection by the human immunodeficiency virus. It was developed by a team of Spanish researchers at the Spanish National Research Council's Biotechnology National Centre headed by Dr. Mariano Esteban. The vaccine is based on the Modified vaccinia Ankara (MVA) virus used during the 1970s to help eradicate the smallpox virus. The B in the name "refers to HIV-B, the most common HIV subtype in Europe". It has been stated by Dr. Esteban that, in the future, the vaccine could potentially reduce the virulence of HIV to a "minor chronic infection akin to herpes".

rVSV-ZEBOV vaccine Vaccine against Ebola virus disease

Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.

<span class="mw-page-title-main">Ebola vaccine</span> Vaccine against Ebola

Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.

M. Juliana “Julie” McElrath is a senior vice president and director of the vaccine and infection disease division at Fred Hutchinson Cancer Research Center and the principal investigator of the HIV Vaccine Trials Network Laboratory Center in Seattle, Washington. She is also a professor at the University of Washington.

A Zika virus vaccine is designed to prevent the symptoms and complications of Zika virus infection in humans. As Zika virus infection of pregnant women may result in congenital defects in the newborn, the vaccine will attempt to protect against congenital Zika syndrome during the current or any future outbreak. As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials. The goal of a Zika virus vaccine is to produce specific antibodies against the Zika virus to prevent infection and severe disease. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of Zika virus infection. Additionally, as dengue virus is closely related to Zika virus, the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue virus infection.

Intrastructural help (ISH) is where T and B cells cooperate to help or suppress an immune response gene. ISH has proven effective for the treatment of influenza, rabies related lyssavirus, hepatitis B, and the HIV virus. This process was used in 1979 to observe that T cells specific to the influenza virus could promote the stimulation of hemagglutinin specific B cells and elicit an effective humoral immune response. It was later applied to the lyssavirus and was shown to protect raccoons from lethal challenge. The ISH principle is especially beneficial because relatively invariable structural antigens can be used for the priming of T-cells to induce humoral immune response against variable surface antigens. Thus, the approach has also transferred well for the treatment of hepatitis B and HIV.

Dan Hung Barouch is an American physician, immunologist, and virologist. He is known for his work on the pathogenesis and immunology of viral infections and the development of vaccine strategies for global infectious diseases.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

References

  1. ↑ Edwin J. Bernard (9 February 2007). "Largest ever African HIV vaccine trial opens in South Africa". aidsmap.com. Aidsmap . Retrieved 22 December 2020.
  2. 1 2 Sekaly, Rafick-Pierre (2008). "The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?". J Exp Med. 205 (1): 7–12. doi:10.1084/jem.20072681. PMC   2234358 . PMID   18195078.
  3. 1 2 Buchbinder, Susan P.; Mehrotra, Devan V.; Duerr, Ann; Fitzgerald, Daniel W.; Mogg, Robin; Li, David; Gilbert, Peter B.; Lama, Javier R.; Marmor, Michael; Del Rio, Carlos; McElrath, M Juliana; Casimiro, Danilo R.; Gottesdiener, Keith M.; Chodakewitz, Jeffrey A.; Corey, Lawrence; Robertson, Michael N. (2008). "Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial". Lancet. 372 (9653): 1881–93. doi:10.1016/S0140-6736(08)61591-3. PMC   2721012 . PMID   19012954.
  4. ↑ Keith Alcorn (22 September 2007). "Merck HIV vaccine fails, trials halted". aidsmap.com. Aidsmap . Retrieved 22 December 2020.
  5. ↑ Gray, Glenda; Buchbinder, Susan; Duerr, Ann (2010). "Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine". Curr Opin HIV AIDS. 5 (5): 357–61. doi:10.1097/COH.0b013e32833d2d2b. PMC   2995949 . PMID   20978374.
  6. ↑ "Statement: An Update Regarding the HVTN 502 and HVTN 503 HIV Vaccine Trials". niaid.nih.gov. 23 October 2007. Retrieved 24 June 2011.
  7. ↑ "Phambili HIV Vaccine Trial Stopped". iavi.org. International AIDS Vaccine Initiative. 23 October 2007. Archived from the original on 27 September 2011. Retrieved 24 June 2011.
  8. ↑ "STEP Study Volunteers to be Informed Whether They Received Vaccine or Placebo" (PDF). Merck Pharmaceuticals. 2007-11-13. Archived from the original (PDF) on August 27, 2008. Retrieved 2008-10-29.
  9. ↑ Alan Aderem (2011). "Fast Track to Vaccines: How Systems Biology Speeds Drug Development". Scientific American (25 April 2011): 66.
  10. ↑ McNeil Jr., Donald (18 May 2012). "Trial Vaccine Made Some More Vulnerable to H.I.V., Study Confirms". The New York Times . New York. ISSN   0362-4331 . Retrieved 25 May 2012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.